Novartis AG (NVS) : Wednesdays money flow analysis of Novartis AG (NVS) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $21.07 million. In comparison, the inflow of money on upticks was a meager $17.01 million. The dollar value of composite uptick trades minus the downtick trades was negative $4.07 million. The uptick to downtick ratio of 0.81 in the money flow shows weakness. The uptick block trades were valued at $2.06 million. The downtick transaction value was high at $8.26 million, which denotes distribution on strength. The uptick to downtick ratio of block trades was 0.25. Hence, the net money flow in the stock was negative ($6.21 million). Novartis AG (NVS) gained $1.37 at $82.9, a change of 1.68% over the previous days close.
Also, Equity Analysts at the Brokerage Firm, Morgan Stanley, downgrades their rating on the shares of Novartis AG (NYSE:NVS). Morgan Stanley has a Underperform rating on the shares. Previously, the analysts had a Equal-weight rating on the shares. The rating by the firm was issued on April 12, 2016.
Novartis AG (NYSE:NVS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $82.00 and $81.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $83.19. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.02, notching a gain of 1.83% for the day. The total traded volume was 1,604,545 . The stock had closed at $81.53 on the previous day.
The stock has recorded a 20-day Moving Average of 2.43% and the 50-Day Moving Average is 4.87%.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.